Bevacizumab solution for intravenous (IV) infusion is TGA approved for treatment of epithelial ovarian, fallopian tube or primary peritoneal cancer for the following indications:
Bevacizumab, in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (International Federation of Gynaecology and Obstetrics (FIGO) Stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other VEGF-targeted angiogenesis inhibitors.
Bevacizumab is also TGA-approved for treatment of metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced, metastatic or recurrent, non-squamous, non-small cell lung cancer, advanced or metastatic renal cell cancer, and grade IV glioma.
Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) inin vitro and in vivo assay systems.
Bevacizumab is a clear to slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion. Bevacizumab is supplied in 100 mg and 400 mg preservative-free, single-use vials to deliver 4 mL or 16 mL of Bevacizumab(25 mg/mL).
Bevacizumab can cause a rare but serious neurologic disorder affecting the brain. Symptoms include headache, confusion, vision problems, feeling very weak or tired, fainting, and seizure (blackout or convulsions). These rare symptoms may occur within hours of your first dose of bevacizumab, or they may not appear for up to a year after your treatment started.